Quantcast

Latest Valeant Pharmaceuticals Stories

2014-05-21 08:30:04

LOS ANGELES, May 21, 2014 /PRNewswire/ -- Research Solutions, Inc. (OTC-PINK: RSSS), a pioneer in facilitating the flow of information from the publishers of scientific, technical, and medical content to enterprise customers in Life Sciences and other research intensive organizations around the world, today announced that Valeant Pharmaceuticals had adopted Bibliogo, the literature management and collaboration web application add-on for the company's Article Galaxy...

2014-05-21 08:29:08

LAVAL, Quebec, May 21, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2014 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker Non-Votes ---- --- -------- ---------------- Ronald H. Farmer 251,288,239...

2014-05-20 12:28:25

LONDON, May 20, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Dermatological Drugs Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/therapeutic/global_dermatological_drugs_market_2014_2018.html TechNavio's analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide....

2014-05-20 08:32:50

LAVAL, Quebec, May 20, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) announced today that the company will host an in-person meeting for Allergan and Valeant shareholders on May 28, 2014 at 8:00 a.m. ET (5:00 a.m. PT) at the AXA Equitable Auditorium, 787 Seventh Avenue (between 51st and 52nd Streets), New York, New York to respond to assertions Allergan has made that the Valeant model is not sustainable, that the Bausch + Lomb portfolio...

2014-05-20 08:31:59

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 20, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding The Chubb Corporation (NYSE: CB), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), AstraZeneca Plc (NYSE: AZN), Mylan, Inc. (NASDAQ: MYL) and Perrigo Co. (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are...

2014-05-13 08:32:00

LAVAL, Quebec, May 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today responded to Allergan, Inc.'s (NYSE: AGN) rejection of Valeant's proposal to combine with Allergan for $48.30 in cash and 0.83 shares of Valeant common stock for each Allergan share: Dear Allergan Shareholders, As you are all aware, yesterday we received Allergan's letter rejecting Valeant's offer. We note that our offer was rejected without Allergan having had any...

2014-05-12 16:29:38

LAVAL, Quebec, May 12, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that certain of its subsidiaries have entered into settlement agreements with affiliates of Actavis plc related to Actavis' generic versions of Acanya® Gel, 1.2%/2.5%, and Tiazac ® XC. Valeant's subsidiaries, Dow Pharmaceuticals Sciences, Inc. and Valeant Pharmaceuticals North America LLC, and Actavis' subsidiary, Watson Laboratories, Inc., entered into...

2014-05-12 08:31:42

DUBLIN, May 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya(® )(clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya(®) Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. Under the terms of the agreement, Valeant will grant...

2014-05-08 08:31:18

LAVAL, Quebec, May 8, 2014 /PRNewswire/ -- -- 2014 First Quarter Total Revenue $1.9 billion; an increase of 77% over the prior year -- Exceeded our expectations -- Launched 11 new products in the U.S. -- Positive organic growth in the U.S. despite the generic impact of Zovirax and RAM coupled with the new generic entry for Vanos -- Bausch + Lomb double-digit organic growth trend continued -- 2014 First Quarter GAAP EPS loss...

2014-05-01 16:33:44

LAVAL, Quebec, May 1, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a live webcast of the company's annual meeting of shareholders. The meeting and webcast will be held on Tuesday, May 20, 2014, at 9:00 a.m. ET at the International Headquarters, Laval Office: 2150 Saint Elzear Blvd. West, Laval Quebec, Canada H7L 4A8. Only shareholders of record at the close of business on the record date will be...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.